Pharmacogenetics: From bench to byte an update of guidelines

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 5, 2011, Pages 662-673

  Swen, J J ^a   Nijenhuis, M ^b   De Boer, A ^c   Grandia, L ^b   Maitland Van Der Zee, A H ^c   Mulder, H ^c,d   Rongen, G A P J M ^e   Van Schaik, R H N ^f   Schalekamp, T ^c   Touw, D J ^g   Van Der Weide, J ^h   Wilffert, B ⁱ   Deneer, V H M ^j   Guchelaar, H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Royal Dutch Association for the Advancement of Pharmacy   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Wilhelmina Ziekenhuis   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Central Hospital Pharmacy   (Netherlands)

^h ST JANSDAL HOSPITAL   (Netherlands)

ⁱ Zorggroep Noorderbreedte ^*  (Netherlands)

^j ST ANTONIUS HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CITALOPRAM; CLOPIDOGREL; DIHYDROPYRIMIDINE DEHYDROGENASE; ESCITALOPRAM; ESOMEPRAZOLE; GENE PRODUCT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCURONOSYLTRANSFERASE 1A1; IMIPRAMINE; MOCLOBEMIDE; NORTRIPTYLINE; OLANZAPINE; OXYCODONE; PANTOPRAZOLE; PAROXETINE; PHENPROCOUMON; PHENYTOIN; PROPAFENONE; RISPERIDONE; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TOLBUTAMIDE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VITAMIN K EPOXIDE REDUCTASE; ZUCLOPENTHIXOL;

ARTICLE; ATAXIA; CONFUSION; CONSTIPATION; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A5 GENE; DPD GENE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DYSARTHRIA; FVL GENE; GENE; GENOTYPE PHENOTYPE CORRELATION; HLA B GENE; HLA B44 GENE; HUMAN; LOADING DRUG DOSE; NAUSEA; NYSTAGMUS; PHARMACOGENETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; TPMT GENE; URINE RETENTION; VKORC1 GENE; VOMITING;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC;

EID: 79955463893     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.34     Document Type: Article

References (14)

1. Mallal, S. et al. HLa-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
2. Flockhart, D.A., Skaar, T., Berlin, D.S., Klein, T.E. & Nguyen, A.T. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86, 109-113 (2009).
3. US Food and Drug administration. Table of Pharmacogenomic Biomarkers in Drug Labels, accessed 15 October 2010.
4. Swen, J.J. et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787 (2008). (Pubitemid 351556025)
5. Van den Besselaar, A.M., Van der Meer, F.J. & Gerrits-Drabbe, C.W. Therapeutic control of oral anticoagulant treatment in The Netherlands. Am. J. Clin. Pathol. 90, 685-690 (1988). (Pubitemid 19006262)
6. Van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PaCT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
7. Kirchheiner, J. et al. CyP2D6 and CyP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulationspecific dosages. Acta Psychiatr. Scand. 104, 173-192 (2001). (Pubitemid 32762271)
8. Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
9. Tan, G.M., Wu, E., Lam, Y.Y. & Yan, B.P. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 11, 439-448 (2010).
10. D'andrea, G. et al. a polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005). (Pubitemid 40070748)
11. Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova, A. & Stafford, D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004). (Pubitemid 38209111)
12. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005). (Pubitemid 40740552)
13. Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004). (Pubitemid 38209110)
14. Vormfelde, S.V. et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CyP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86, 54-61 (2009).